Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Mouse Model to Validate Drugs Targeting DUX4 Enhancer/Promoter Activity
Investigator: Yosuke Hiramuki, Ph.D. at the University of Nevada, Reno We created a mouse model to validate the effect of drugs targeting DUX4 gene expression in a whole living organism.…
Read MoreTesting the efficacy of CRISPRi in FSHD2
Investigators: Takako Jones, PhD and Charis L. Himeda, PhD; University of Nevada, Reno School of Medicine The goal of this proposal is to test the utility of our CRISPR inhibition…
Read MoreAll-in-one CRISPR inhibition for FSHD1 and FSHD2
Investigator: Charis L. Himeda, PhD, Research Assistant Professor Research Institution: Peter Jones Lab, University of Nevada, Reno School of Medicine, Reno NV USA The most direct path to an FSHD…
Read MoreBio-Marker Project
Investigator: Robert J Bloch PhD, Professor of Physiology at the University of Maryland Recent studies from my lab have shown that a protein, called “SLC34A2” (not a name to trip…
Read MoreOptimizing Gapmer Therapy for Facioscapulohumeral Muscular Dystrophy
Principle Investigator: Yi-Wen Chen Research Institution: George Washington School of Medicine Antisense oligonucleotide (AON) therapy is a promising approach to treating FSHD. However, several issues arise with AONs including: difficulty…
Read MoreIn vivo model to validate drugs targeting DUX4 enhancer/promoter activity
Principle Investigator: Yosuke Hiramuki (at Peter Jone’s laboratory) Research Institution: University of Nevada DUX4 is normally expressed in testis in healthy individuals and aberrantly expressed in specific skeletal muscles of…
Read More